top of page


Medicinal cannabis: the production chain that CEIS didn't plan
Ou: a cadeia que nasceu de uma sentença Since August 4th, ANVISA (Brazilian Health Regulatory Agency) has been receiving requests for Special Authorization from companies interested in cultivating Cannabis sativa in Brazil for medicinal purposes. This date marks the operational start of a new production chain, but news reports still primarily treat the issue as another step in the regulation of cannabis. The most interesting aspect lies elsewhere: the timeline for medicinal c
Aug 185 min read


Only 10% of Brazilian Invention Patents Originate in Brazil: What Does This Mean for Our Sovereignty?
Technological innovation is a fundamental factor for a country’s economic development and competitiveness. In Brazil, intellectual...
Mar 9, 20254 min read


The Importance of Regulatory Agencies in Health Innovation and Pharmaceutical Regulation: FDA, EMA, and ANVISA in Perspective
Health innovation and the remarkable growth of the pharmaceutical sector—with a projected global revenue of USD 1.155 trillion in...
Nov 1, 20244 min read
bottom of page
